Source:http://linkedlifedata.com/resource/pubmed/id/21298467
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2011-4-19
|
pubmed:abstractText |
The diagnostic utility of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer (EPC) has not been properly studied, and few reports have analysed a clinically relevant spectrum of patients. The objective was to evaluate the clinical validity of detecting K-ras mutations in the diagnosis of EPC in a large sample of clinically relevant patients. We prospectively identified 374 patients in whom one of the following diagnoses was suspected at hospital admission: EPC, chronic pancreatitis, pancreatic cysts, and cancer of the extrahepatic biliary system. Mutations in the K-ras oncogene were analysed by PCR and artificial RFLP in 212 patients. The sensitivity and specificity of the K-ras mutational status for the diagnosis of EPC were 77.7% (95% CI: 69.2-84.8) and 78.0% (68.1-86.0), respectively. The diagnostic accuracy was hardly modified by sex and age. In patients with either mutated K-ras or CEA > 5 ng/ml, the sensitivity and specificity were 81.0% (72.9-87.6) and 62.6% (72.9-87.6), respectively. In patients with mutated K-ras and CEA > 5 ng/ml the sensitivity was markedly reduced. In comparisons with a variety of non-EPC patient groups sensitivity and specificity were both always greater than 75%. In this clinically relevant sample of patients the sensitivity and specificity of K-ras mutations were not sufficiently high for independent diagnostic use. However, it seems premature to rule out the utility of K-ras analysis in conjunction with other genetic and 'omics' technologies.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1573-7284
|
pubmed:author |
pubmed-author:AlguacilJoanJ,
pubmed-author:CarratoAlfredoA,
pubmed-author:CorominasJosep MJM,
pubmed-author:FernandezEsteveE,
pubmed-author:GuarnerLuisaL,
pubmed-author:Hernández-AguadoIldefonsoI,
pubmed-author:LópezTomàsT,
pubmed-author:LumbrerasBlancaB,
pubmed-author:MalatsNúriaN,
pubmed-author:ParkerLucy ALA,
pubmed-author:PortaMiquelM,
pubmed-author:RealFrancisco XFX,
pubmed-author:RifàJuliJ
|
pubmed:issnType |
Electronic
|
pubmed:volume |
26
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
229-36
|
pubmed:meshHeading |
pubmed-meshheading:21298467-Aged,
pubmed-meshheading:21298467-Aged, 80 and over,
pubmed-meshheading:21298467-Female,
pubmed-meshheading:21298467-Genes, ras,
pubmed-meshheading:21298467-Humans,
pubmed-meshheading:21298467-Male,
pubmed-meshheading:21298467-Middle Aged,
pubmed-meshheading:21298467-Mutation,
pubmed-meshheading:21298467-Pancreatic Neoplasms,
pubmed-meshheading:21298467-Polymerase Chain Reaction,
pubmed-meshheading:21298467-Polymorphism, Restriction Fragment Length,
pubmed-meshheading:21298467-Prospective Studies,
pubmed-meshheading:21298467-Reproducibility of Results,
pubmed-meshheading:21298467-Sensitivity and Specificity
|
pubmed:year |
2011
|
pubmed:articleTitle |
Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients.
|
pubmed:affiliation |
Department of Public Health, Miguel Hernández University, Alicante, Spain.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study
|